Screener
GeneDx Holdings WGS Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Gross profit | 68,211 | 58,476 |
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
| Impairment loss | 31,287 | — |
| Loss from operations | (57,471) | (4,551) |
| Non-operating (expenses) income, net | ||
| Change in fair value of financial liabilities | 2,540 | (1,100) |
| Interest expense, net | (717) | (640) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's impairment charges?
- GeneDx Holdings (WGS) reported impairment charges of $31.29M in Q1 2026.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about GeneDx Holdings's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude